Registry-listed formulations

efbemalenograstim alfa · mesh:C000731753

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

2 source entries across 2 studies. This list may not include all unresolved or historical entries.

Efbemalenograstim alfa InjectionRegistry intervention
Linked study entry; product equivalence not established
View study and source
Efbemalenograstim alfa InjectionRegistry intervention
Linked study entry; product equivalence not established
View study and source

Success Metrics

Active Trials

2(67%)

Phase Distribution

Phase 2

67%

Not Applicable

33%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution3 total trials

Phase 2Efficacy & side effects

2(66.7%)

N/ANon-phased studies

1(33.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(3)

Detailed Status

Recruiting2

Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

N/A

Most Advanced

Phase 2

Trials by Phase

Phase 22 (66.7%)

N/A1 (33.3%)

Trials by Status

not_yet_recruiting133%

recruiting267%

Recent Activity

2 active trials

Showing 3 of 3

recruitingphase_2

Efbemalenograstim Alfa for Primary/Secondary Prevention in Patients With Solid Tumors at High Risk for Febrile Neutropenia (FN) or Intermediate Risk of Chemotherapy Regimens Associated With Other Risk Factors in FN

NCT07187908

not_yet_recruitingnot_applicable

A Multi-cohort Study of Efbemalenograstim Alfa Injection for Preventing ANC Reduction in Solid Tumor Patients Post Immune-chemotherapy.

NCT06649448

recruitingphase_2

Efbemalenograstim Alfa Injection for Ovarian or Cervical Cancer Receiving Chemotherapy Regimen

NCT06251947

Clinical Trials (3)

Showing 3 of 3 trials

NCT07187908Phase 2

Efbemalenograstim Alfa for Primary/Secondary Prevention in Patients With Solid Tumors at High Risk for Febrile Neutropenia (FN) or Intermediate Risk of Chemotherapy Regimens Associated With Other Risk Factors in FN

Recruiting

NCT06649448Not Applicable

A Multi-cohort Study of Efbemalenograstim Alfa Injection for Preventing ANC Reduction in Solid Tumor Patients Post Immune-chemotherapy.

Not Yet Recruiting

NCT06251947Phase 2

Efbemalenograstim Alfa Injection for Ovarian or Cervical Cancer Receiving Chemotherapy Regimen

Recruiting

All 3 trials loaded